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This thesis describes work performed at the intersection of coagulation and livcr disease. Chapter I
relates thc work in this thcsis to previously perÍbrrned studies and extcrnal developments. A short
introduction in haunophilia, coagulation disordcrs in liver discase and current views on the




C-'hapter 2 cousists of a review of l i terature on hepatit is C (HCV) in haernophil ia patients. Allcl
some background informatior.r, the prevalence of infection is discussed. Subsequently, studics on the
clinical course of chronic hepatit is C are reviewed. The second half of t lre paper discusses data on
treatment of chronic hepatitis C infection in haemophilia patients.
We concluded that thc burden of liver disease in haernophilia patients will probably increase in thc
next l0 to 20 years. Tre-atment of chronic hepatitis C is available but at the tirne of writing only
effective in about 40% of patients. Therc is uo conseusus on who should and who shotrld not be
treated. If treatment is opted fog conrbination thcrapy of interfcron and ribavirin must be first
choice. The optinral dose of interferon and lcngth of treatmcnt is not yet known.
Chaptcrs 3 and 4 dcscribe studies on lymphocyte subsets in haemophilia patients. Abnormal
lyrnphocyte subsets in human irnmunodeficiency virus (HIV) negative hacmophilia patients have
bcen described previor-rsly in detail, bLrt thcir cause remains unclear. Treatment with irnpurc
concentratcs has been inrplicated but it has also been hypothesized that, in parallei rvith HIV
infection. HCV inlection can bc the cause of these abnonnalit ics.
ln chapter 3, we indirectly compared two different groups of HCV positive, HIV negative
haemophilia patients. We dcscribed seven scvere haemophilia B patients, bcfore and after
substitution was changcd from prothrombin complex concentrate to nlonoclonally purified
concentrate. Data were compared with healthy controls and previous findings in haemophilia A
patients.
At baseline, haemophil ia B patients did not differ from controls. Aftcr two years, T helper cells
showed an increase, while a rise in B cells approached statistical significancc. In contrast,
haemophilia A paticnts sl.rowed increascd numbers of activated non-B lyrnphocytes and lowcred
numbers of B cells at baselinc as compared to controls. After two years activated non-B
lymphocytes decrcasecl, as did the CD4ICDS ratio, duc to increasing numbers of CDS positivc cells.
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rccovered after changing therapy to a monoclonally purif ied product. These findings contrasted with
the excessive immune stimulation in haernophil ia A. Wc concluded that this differencc docs not
support a causativc rolc for hepatitis C.
In chapter 4, we compared lymphocyte subsets in 20 HIV negative, HCV positive haemophil ia A
paticnts and in l4 non-haemophil iacs with chronic hepatit is C to those in 18 healthy controls. In
haernophil ia patients, highcr numbcrs of T lymphocytes and activated CDS positive cells, lower
numbcrs of B lymphocytes and a normal CD4/CD8 ratio were seen. These differences were either
not demonstrated in hepatitis C controls or wcrc lcss pronounced and in the opposite direction. From
this study, we concluded that haemophil ia A patients show abnormalit ies in lymphocytc subscts that
could not bc attributed to chronic hepatit is C.
In both studies, we speculated whether the obscrvcd diffcrenccs rnight be due to the administered
concentratcs.
Chapter 5 is concerned with the natural history of hepatit is C. Most availablc data have limited
usefulness for counsell ing patients and planning treatment, as they comc from highly sclccted
patient groups. This l imitation can be overcome in patients with haemophil ia or other congenital
coagulation disorders who are followed for their primary disorder irrcspcctivc of l ivcr discasc. Thcy
forrn a homogeneous, well-defined group with a known mode and duration of infection. We studied
a group of 45 HCV-RNA positive, HIV negative paticnts, mainly haemophil iacs, from our centre.
Norrc had received specific therapy for chronic hepatitis C.
A prospective protocol of mcdical history, physical examination, laboratory tests and abdorninal
ultrasonography was performed in all patients. Patients were classificd according to rcsults of
ultrasonography.
Wc found that two patients had experienced an episode of variceal blccding, all othcrs wcrc
asyrnptomatic. None had ascites. HCV-RNA titers were >500.000 copies/rnl in 23 paticnts,
genotype was I in 3l paticnts. Forty (89%) had elevated transaminases, l iver synthesis Íunction was
diminished in 7 (16%), platelet count in 8 ( l8%). Ultrasonography was normal in 26 (58%) patients
wlri le l2 (27%) had isolated splenomegaly and 7 (16%) had liver nodularity cornpatible with
cirrhosis. Univariate analysis disclosed higher transaminases and "yG! older agc at acquisit ion of
infection and older present age as risk factors for more advanced disease. Of these, only oldcr
present age was an independent prcdictor in n.rultivariate analysis. We concluded that a rnedian l9
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years after infection. 58% of patients had no other signs of l iver disease than raised transaminases
and l60,í had cirrhosis on ultrasonography. Only 245 patients haci symptomatic diseasc. Older
prescnt age was in this group the rnain risk factol for advanced diseasc.
ln chaptcr 6, we describcd a multicentrc,
induction dosed interferon-alpha combined
disorclers and chronic hepatit is C.
As revic-wed in chapter 2, many patients
hepatit is C. In chaptcr 5, we showed that a
patients has signs of l ivcr diseasc.
Standard therapy for chronic hepatit is C is a combination of interferon-alpha nd ribavirin. Pilot
studies har,'c reported higher sr-rcces rates whcn interf 'cron-alpha therapy is startcd with a high dose
induction schemc, but thc saÍèty and Í 'easibil i ty of very high doses of interferon-alpha is doubted
and no double-blincl comparisor.rs of differcnt doses are available. Wc rvanted to assess if starting
combinalion therapy for chronic hepatit is C with an induction dose of interferon-alpha was feasible
and wor.rld increase rcsponse.
Sirty-six patients lvith congenital coagulation disorders and chronic hepatit is C from six Dutch
haemoplri l ia centrcs were included. Tlrey received either 5 MU interferon twice daily (induction
therapy) plus ribavirin for for.rr wceks or 5 MU intc-rferon every seconcl day (standard therapy) plus
ribavirin lbr 4 r'r,e-eks, in both groups fcrllowed by interferon ó MU every second day for anothcr 48
and ribar"irin for another 22 weeks. We defined sustained response as negative HCV-RNA PCR at 6
turonths aftcr the end of one-year therapy Adverse events were monitored.
Sustainecl response was 579í in induction therapy versus 4l7o in standard thcrapy (p 0.215). Dose
adjustments were necded in 53% ofpatients (62% in induction therapy. 4loÁ in standard thcrapy, p
0.093). Treatmcnt was pÍematurcly discontinued in 89í of patients.
We concluded that the overall ratc of sustained response in this trial was high and that, although no
statistically significant difference between induction and standard thcrapy could be demonstrated
all conrparisons Íavoured induction therapy. hrduction therapy was safc and feasible, even ln
hernophilia patients, although intensive monitorin-9 and frequent dose adjustments were necessar)i
Double-blind cornparisons of interferon-alpha doses and the use of placebo injections were realistic.
In chapter 7, wc reported three cases of clinical experience rvith recombinant factor VIIa (rFVIIa),
one in a patient l l , i th acquircd thrornbocytopathia and two in patients with vascular pathology.
randornised, double-blind, placcbo-controlled trial of
with ribavirin in patients with congenital coa-rlulation
with congenital coagulation disorders have chronrc
significant proportion of an unselccted group of this
Si rnr,rr<r
C-'haptcrs 8, 9 and 10 describc difïèrent aspects of a pilot trial of TFVIIa in orthotopic l ivcr
transplantation (OLT). Frorn a hacmatological vie*,point. OLT is chalacteriscd by e.rtensive
vascular darnage in a coagulation-cotnpror.r.rised patient. Control of blccding has been a major
challenge from the start of OLT. It was shown that large transfusion requirements, i.r-. cxcessive
blood loss, cluring OLT are correlatecl vvith increasc-d rnorbidity and rnortality.
Recombinant FVlla has in.rproved haemostasis in a varicty of conditions, but had never been studied
in l iver transplantation. We perfonned a single centre, open labcl, pilot study in six adult patients
unclergoing OLT lbl cirrhosis Child-Pu-rrh B or C. Eighty prg TFVIla/kg was adnrinistered at t lre start
of the operation. Packcd red blood cells (RBC), Í iesh frozen plasrna (FFP) and platelet concentrates
(PC) were admirristcrcd according to prcdcfined criteria.
Chapter 8 focuses on safety and efficacy of rFVlla in OLT. Pcrioperative transfusion requirements
in six study patients were colrparcd to rnatched controls, adverse events wc-rc monitored.
Trattsfusion requirenrents [nrcdian (range)] r.verc lou,er in the str"rdy group than iu matclred controls:
1.5 (0-5)  versus 7 (2-  18)  uni ts  a l logeneic RBC, 0 (0-2)  versus 3.5 (0-23)  uni ts  auto logous RBC, tota l
amount of RBC 3 (0-5) versus 9 (4-40) units. Transfused FFP was I (0-7) versus 8 (2-35) units.
Blood loss u,as 3.5 L (1.4--5.3)  versus 9.8 L (3.7-35.0) .  A l l  d i f le lences wcrc stat is t ica l ly  s igni f icant .
One study patient developed an hcpatic artery thrombosis at day I postoperativcly.
We concluded that a single closc of 80 pg/kg TFVIIa significantly reduced transfusion requirements
clulirrg OLT and that furfhcl study rvas needed to cstablish the optirnally cffective and salè dose o1'
rFVIla in this setting
ln chapter 9. w'c assessecl the eÍfect of TFVIIa on coagulation and fibrinolvsis during OLT.
In the six patients who hacl reccived a single dose of 80 ptg/kg TFVIIa and in tcn untreated controls.
coagulation factors, paranrctcrs of thrornbin gcncration and parameters of f ibrinolysis wcrc
mcasured dr-rring and aftcr OLT.
We found that coagulation factor concentrations did not differ between paticnts and controls.
Thlornbin generation did not rise after thc administration of rFVIIa, but did sharply incrcase afïer
reperlusion in 1'ratients as cotnpared to controls. No difference in fibrinolysis was seen between
patients and controls. No evidence of cliffusc intravascular coagulation was seen.
Wc concluded that the usc of rFVlla in OLT cnhanced thrornbin generation in a localized and time-
linrited rnáltter. u,ithoLrt causi ng systclnic coaguletion.
a
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Chapter l0 exarnines whether the haemostatic effects of TFVIIa in patients with cirrhosis, in a stable
situation or during the OLT pilot stLrdl'. might be cxplained in part by enhanced ownregulation of
fibrinolysis by the thronrbin activatable fibrinolysis inhibitor, TAFI. Addition of therapeutical or
supratherapcutical doses of rFVlla to plasma of l2 patients with stable cirrl.rosis did not result in a
prolongation of clot lysis timc, whereas clotting times wcre significantly reduced. Also, clot lysis
assays of plasma sarnples taken during and aftcr OLT, in study patients and controls, did not show
any efïèct of rFVlla on plasma fibrinolytic potential. We concluded that this study shorved no
evidencc for an antif ibrinolytic clÍbct of TFVIIa in cirrhotic patients.
We started this projcct with a fèw clear questions, as explicatcd in Chapter l. Regarding the immune
abnormalit ies in HIV ncgative haemophil ia patients, we have dcmonstrated that hepatit is C infection
is not the car.rse. Whether thc r,rse of inrpurc concentrates i , rerlains irnclear. During the span of this
thesis no clinical implications have c'rnerged, but follou,-up wil l go on. We must remain watchful for
ncw cornplications of therapy with coagulation Íàctor concentrates.
We showed that hepatit is C has caused significant l iver damage in our patient group and we expect
rnore clinical l iver disease in the future. Sadly, two deaths duc to l iver discase have occurrecl in our
cr-ntre in the last years. Thc satèty of concentrates has irrcreased grcatly aÍierthe catastloplre of HIV
inÍèction, and nerv hepatitis C inÍ-ections have r.rot occurrcd. Howeveq for previously infected
paticnts, chronic hcpatit is C rcmains a real and ongoing threat. They have a right to the best chanccs
ofcurc from this disease.
Therapy for chronic lrcpatit is C has gleatly improvetl u,ith thc introdr"rction of ribavirin. We showed
that with high-dosed combination therapy 507o sustained responsc is possible. We did collcct data
to answcr tl.re question whether thc imrnune abnormalities are related to success of trcahnent, but
thesc are not yet analysed.
High costs should not be an irnpcdiment o an effecti l 'e and safe treatrl lelrt of haemophil ia. A
significant part of our knowledge oltrombosis and haemostasis i  derived from haemophil ia nd
other congenital coagulation disorders. This has bencfitted the trcatment of other patient groups.
The use of recombinant factor Vlla is recent examDle of this.
